A single-arm, open label, multi-center phase I/II trial to assess the safety and efficacy of BIBF 1120 added to low-dose cytarabine in elderly patients with AML unfit for an intensive induction therapy

Beteiligte Wissenschaftler:
Akad. Rat Dr. Dipl.-Stat. J. Gerß
Dipl.-Stat. M. Eveslage
Dr. rer. medic. Dipl.-Math. R. Koch

Studienleitung:
PD Dr. med. U. Krug (Medizinische Klinik und Poliklinik A, UK Münster)
PD Dr. med. C. Schliemann